Grail wants to develop a test for cancer at the earliest possible stage. Illumina, the maker of DNA-sequencing technology, teamed up with a group of Silicon Valley investors to develop a blood test for any kind of cancer at an earlier stage than previously possible.
Using Illumina's technology, a new company called Grail will look for a way to measure circulating nucleic acids — bits of DNA that circulate in the blood outside blood cells. While most of our DNA is inside our cells, scientists use CNAs to test for cancer and other diseases noninvasively. Its ambitious mission: Develop a universal cancer-screening test.
$100 million from investors, including Arch Venture Partners, Bezos Expeditions, Bill Gates, and Sutter Hill Ventures. Illumina remains majority shareholder.
Tags: MedTech startups, DNA, Cancer, Oncology, Illumina,